Incidence of and risk for osteonecrosis of the jaw in Korean osteoporosis patients treated with bisphosphonates: A nationwide cohort-study

被引:17
|
作者
Kim, Se Hwa [1 ]
Lee, Young-Kyun [2 ]
Kim, Tae-Young [3 ]
Ha, Yong-Chan [4 ]
Jang, Sunmee [5 ,6 ]
Kim, Ha Young [7 ,8 ]
机构
[1] Catholic Kwandong Univ, Int St Marys Hosp, Dept Internal Med, Coll Med, Incheon, South Korea
[2] Seoul Natl Univ, Bundang Hosp, Dept Orthopaed Surg, Seongnam, South Korea
[3] Konkuk Univ, Sch Med, Dept Orthopaed Surg, Seoul, South Korea
[4] Chung Ang Univ, Dept Orthopaed Surg, Coll Med, Seoul, South Korea
[5] Gachon Univ, Coll Pharm, Incheon, South Korea
[6] Gachon Univ, Gachon Inst Pharmaceut Sci, Incheon, South Korea
[7] Wonkwang Univ, Sanbon Hosp, Dept Internal Med, Coll Med, Gunpo, South Korea
[8] Univ Ulsan, Gangneung Asan Hosp, Dept Internal Med, Coll Med, Kangnung, South Korea
关键词
Bisphosphonates; Osteonecrosis of the jaw; Osteoporosis; Periodontal disease; SUPPRESSED BONE TURNOVER; ZOLEDRONIC ACID; POSTMENOPAUSAL OSTEOPOROSIS; RHEUMATOID-ARTHRITIS; ALENDRONATE; FRACTURES; WOMEN; ASSOCIATION; PREVALENCE;
D O I
10.1016/j.bone.2020.115650
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: To estimate the incidence of osteonecrosis of the jaw (ONJ) in patients treated with bisphosphonates (BPs) and to identify clinical risk factors that increase the risk for ONJ in Korean osteoporosis patients. Methods: We used data acquired from the Korean National Health Insurance Service. Among 2,140,149 participants with osteoporosis in 2012, we selected 164,926 new BP users and 164,926 ageand sex-matched control subjects. The control group included only patients with no prescriptions for BPs between January 1, 2011, and December 31, 2016. Participants were followed for 4 years. Results: Over the 4-year follow-up period, the cumulative incidence rates of ONJ were 20.9 and 6.9 per 100,000 person-years in the BP and control groups, respectively. The BP group had an increased risk for ONJ compared to the control group after adjusting for multiple variables (hazard ratio [HR] 3.72, 95% CI 2.70-5.11). Advanced age (>= 70 years), comorbid diseases such as diabetes, hypertension, and rheumatoid arthritis (RA) were independent risk factors for the development of ONJ. In addition, tooth extraction (HR 9.85), gingivitis, and periodontal disease (HR 4.78) were strongly associated with ONJ. Conclusions: ONJ incidence was 21 per 100,000 person-years in osteoporosis patients receiving bisphosphonates. Clinical factors including advanced age, diabetes, RA, dental disease, as well as BP use were significantly associated with ONJ.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study
    Yamazaki, T.
    Yamori, M.
    Ishizaki, T.
    Asai, K.
    Goto, K.
    Takahashi, K.
    Nakayama, T.
    Bessho, K.
    INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2012, 41 (11) : 1397 - 1403
  • [2] Osteonecrosis of the Jaw in Older Osteoporosis Patients Treated with Intravenous Bisphosphonates
    Baillargeon, Jacques
    Kuo, Yong Fang
    Lin, Yu-Li
    Wilkinson, Gregg S.
    Goodwin, James S.
    ANNALS OF PHARMACOTHERAPY, 2011, 45 (10) : 1199 - 1206
  • [3] Incidence and risk predictors for osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates
    Kos, Marcin
    ARCHIVES OF MEDICAL SCIENCE, 2015, 11 (02) : 319 - 324
  • [4] THE INCIDENCE OF JAW OSTEONECROSIS IN MULTIPLE MYELOMA PATIENTS TREATED WITH BISPHOSPHONATES
    Kraj, M.
    Poglod, R.
    Maj, M.
    Owczarska, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 269 - 269
  • [5] Jaw Osteonecrosis in Patients Treated with Bisphosphonates: An Ultrastructural Study
    Perrotta, I.
    Cristofaro, M. G.
    Amantea, M.
    Russo, E.
    De Fazio, S.
    Zuccala, V.
    Conforti, F.
    Amorosi, A.
    Donato, G.
    Tripepi, S.
    Giudice, M.
    ULTRASTRUCTURAL PATHOLOGY, 2010, 34 (04) : 207 - 213
  • [6] Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis
    Everts-Graber, Judith
    Lehmann, Daniel
    Burkard, John-Patrik
    Schaller, Benoit
    Gahl, Brigitta
    Haeuselmann, HansJoerg
    Studer, Ueli
    Ziswiler, Hans-Rudolf
    Reichenbach, Stephan
    Lehmann, Thomas
    JOURNAL OF BONE AND MINERAL RESEARCH, 2022, 37 (02) : 340 - 348
  • [7] Risk of Osteonecrosis of the Jaw under Denosumab Compared to Bisphosphonates in Patients with Osteoporosis
    Everts-Graber, J.
    Lehmann, D.
    Burkhard, J. P.
    Schaller, B.
    Gahl, B.
    Hauselmann, H. J.
    Studer, U.
    Ziswiler, H. R.
    Reichenbach, S.
    Lehmann, T.
    SWISS MEDICAL WEEKLY, 2022, 152 : 8S - 8S
  • [8] Dose-Intensity of Bisphosphonates and the Risk of Osteonecrosis of the Jaw in Osteoporosis Patients
    Jung, Sung-mok
    Han, Sujeong
    Kwon, Hye-Young
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [9] Incidence Rate of Potential Osteonecrosis of the Jaw Among Women with Postmenopausal Osteoporosis Treated with Prolia or Bisphosphonates
    Xue, Fei
    Wagman, Rachel B.
    Yue, Susan
    Smith, Shawna
    Arora, Tarun
    Curtis, Jeffrey R.
    Ehrenstein, Vera
    Sorensen, Henrik T.
    Tell, Grethe
    Kieler, Helle
    Wang, Florence T.
    Dore, David D.
    Sprafka, J. Michael
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [10] OSTEONECROSIS OF THE JAW IN PATIENTS WITH OSTEOPOROSIS RECEIVING ORAL BISPHOSPHONATES
    Dalai, C.
    Ciavoi, G.
    Suciu, R.
    Cioara, F.
    Pascalau, N.
    OSTEOPOROSIS INTERNATIONAL, 2016, 27 : S443 - S443